Evidence-based guideline update: Plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

ABSTRACT:

Objective

To reassess the role of plasmapheresis in the treatment of neurologic disorders.

Methods

We evaluated the available evidence based on a structured literature review for relevant articles from 1995 through September 2009. In addition, due to revision of the definitions of classification of evidence since the publication of the previous American Academy of Neurology assessment in 1996, the evidence cited in that manuscript was reviewed and reclassified.

Results and recommendations

Plasmapheresis is established as effective and should be offered in severe acute inflammatory demyelinating polyneuropathy (AIDP)/Guillain-Barré syndrome (GBS) and in the short-term management of chronic inflammatory demyelinating polyneuropathy (Class I studies, Level A). Plasmapher

SUBMITTER: Cortese I 

PROVIDER: S-EPMC3034395 | biostudies-literature | 2011 Jan

REPOSITORIES: biostudies-literature